BeOne Medicines, formerly known as BeiGene (ONC), announced its new name and redomiciliation to Switzerland are officially in effect, marking a significant milestone in the company’s evolution. The new name and redomiciliation to Switzerland from the Cayman Islands were approved by shareholders on April 28. The transition to the BeOne name across the company’s worldwide operations on six continents will happen in phases.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene receives positive CHMP opinion for Tevimbra
- BeiGene: Strong Sales and Promising Pipeline Drive Buy Rating
- BeiGene Holds Annual Shareholders Meeting, Key Resolutions Passed
- BeiGene price target raised to $350 from $348 at Guggenheim
- BeiGene’s Strong Market Position and Promising Financial Outlook Drive Buy Rating